Colorectal cancer trials

AI-generated summary

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies is being studied. Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer +3 • Eligibility: Inclusion Criteria (Key Factors): 1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: * Participant is intolerant of existing therapy(ies) known…. Goal: RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. Phase/Status/Sponsor: Unknown phase; RECRUITING; RasCal Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases". is being studied. Conditions: Chronic Liver Disease and Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease +4 • Eligibility: Inclusion Criteria: 1. Patients * diagnosed with chronic liver disease (viral or not) * diagnosed with at least one liver nodule for which a biopsy is planned as…. Goal: Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut National de la Santé Et de la Recherche Médicale, France.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. is being studied. Conditions: Metastatic Solid Tumors, Stage 4 Cancer • Eligibility: Inclusion Criteria: 1. Life expectancy of at least 90 days. 2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have…. Goal: This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Phase/Status/Sponsor: Unknown phase; RECRUITING; New Phase Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BBO-11818 in Adult Subjects With KRAS Mutant Cancer is being studied. Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma +11 • Eligibility: Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation *…. Goal: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors is being studied. Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland +7 • Eligibility: Inclusion Criteria: This study will look at solid tumors (as a basket trial for any solid cancer) with HER2 positivity based on IHC Procurement Inclusion Criteria 1. The…. Goal: This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma is being studied. Conditions: Mesothelioma, Thymoma, Pancreatic Neoplasms +2 • Eligibility: * INCLUSION CRITERIA: * All participants greater than or equal to 2 years of age with malignant mesothelioma. * All participants greater than or equal to18 years of…. Goal: Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests adding PDS01ADC to a liver-directed chemotherapy approach (HAIP with FUDR and dexamethasone) plus standard systemic chemotherapy for certain liver cancers. It is for adults 18 and older with unresectable cancer confined to or dominant in the liver, specifically metastatic colorectal cancer to the liver, intrahepatic cholangiocarcinoma, or adrenocortical carcinoma with liver metastases. The study aims to learn the objective response rate, i.e., how often tumors shrink, with this combination therapy. Eligible participants must have had first-line systemic chemotherapy and will receive HAIP-delivered chemotherapy, PDS01ADC injections every four weeks, and ongoing systemic chemotherapy. Exclusions include active autoimmune disease (with some steroid replacement exceptions), active hepatitis B or C infection, significant cardiovascular disease, prior FUDR exposure, and other factors that could confound results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests nanvuranlat in adults with biliary tract cancer to find a recommended dose regimen (Part A) and to study its effect on overall survival compared with the physician’s best choice (Part B). Participants are 18 years or older with advanced, metastatic, or unresectable BTC who have received one prior platinum-based therapy. Treatments are given every two weeks with safety checks, tumor imaging, and exploratory tests to understand how the drug works. Key exclusions include active CNS metastases, significant cardiovascular disease, HIV not on therapy, active HBV or HCV infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests precision-based immunotherapy approaches for primary liver cancer (hepatocellular carcinoma and cholangiocarcinoma) and aims to build a biospecimen repository to study the biology of the cancer and how patients respond to treatment. - It will enroll adults 18 and older with liver cancer who are receiving or planning to receive immunotherapy, and will collect medical records, imaging, tumor tissue, and samples such as blood, urine, and stool over time. - Researchers will perform a wide range of analyses (genomics, epigenetics, metabolomics, microbiome, and immune monitoring) to identify factors that predict response or resistance to immunotherapy and to understand disease progression. - HIV infection is an exclusion criterion, and the study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether adding durvalumab to the chemotherapy drugs gemcitabine and cisplatin given before surgery helps treat high-risk, resectable intrahepatic cholangiocarcinoma (liver cancer). - It is for adults who are considered candidates for curative surgery. - Researchers want to learn how many patients can complete the pre-surgery therapy and then have the tumor completely removed, as well as rates of major tumor response and overall survival after treatment. - Key exclusions include pregnancy, active autoimmune diseases, active infections (including hepatitis B or C), recent major surgery or current immunosuppressive therapy, and other conditions that could affect safety or results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biobank for Cholestatic Liver Diseases. is being studied. Conditions: Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma +1 • Eligibility: Inclusion Criteria: PSC * Patients diagnosed with PSC and who are between the age of 18 and 85 at time of enrollment in the study. * The diagnosis…. Goal: This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a phase I dose-escalation trial testing AU409, an RNA transcription modulator, to find the safest and recommended dose and to study its safety in adults with advanced liver cancers or solid tumors that have spread to the liver. Eligible participants are adults 18 and older with an advanced solid tumor that has exhausted standard treatments (or no good options), especially with liver-dominant disease or primary liver cancer; exclusions include untreated brain metastases, serious heart problems, active hepatitis B, pregnancy, or recent anticancer therapy. The study aims to determine the maximum tolerated dose and the recommended phase II dose and to assess safety and how AU409 behaves in the body. It will also look for early signs of anti-tumor activity on imaging and may collect tumor tissue and blood samples for analysis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests BOLD-100 given with the chemotherapy FOLFOX in adults with advanced gastrointestinal cancers (such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma) to assess safety and tolerability, using a dose-escalation phase followed by expansion. - In the colorectal cancer arm (Arm VII), eligible patients who are oxaliplatin-naïve and have had only one prior metastatic therapy will be randomized to three groups: BOLD-100 at 500 mg/m2 with FOLFOX, BOLD-100 at 625 mg/m2 with FOLFOX, or FOLFOX alone, with quality-of-life assessments. - The trial aims to learn whether adding BOLD-100 provides anti-tumor activity and how it affects patients’ quality of life, while establishing safe dose levels. - Key exclusions include neuropathy greater than grade 2, CNS metastases, active HIV on ART, DPD deficiency, prior exposure to BOLD-100 (for Arm VII), MSI-H tumors, and recent major treatments or other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors is being studied. Conditions: Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer +1 • Eligibility: 1. Willing to sign the informed consent form and follow the requirements specified in the protocol. 2. Life expectancy ≥ 3 months. 3. Tumor specimen available for CDH17…. Goal: This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; ArriVent BioPharma, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial compares rilvegostomig plus gemcitabine and cisplatin versus durvalumab plus gemcitabine and cisplatin as first-line treatment for advanced biliary tract cancer. - It is for adults with unresectable locally advanced or metastatic BTC, including intrahepatic or extra-hepatic cholangiocarcinoma and gallbladder cancer, who have not yet received systemic therapy for advanced disease and have measurable disease with good performance status. - The study aims to learn which regimen provides better efficacy and acceptable safety when used at the start of treatment. - Key exclusions include ampullary cancer, prior systemic therapy for unresectable or metastatic BTC, prior exposure to immune-targeting therapies, active autoimmune disease requiring steroids, and certain interstitial lung disease or serious skin conditions. - Sponsor: AstraZeneca; Status: Recruiting; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) is being studied. Conditions: Colorectal Neoplasms • Eligibility: The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: Inclusion Criteria include, but are not limited to: * Has a histologically…. Goal: In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials is being studied. Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS +9 • Eligibility: Inclusion Criteria: Patient must be ≥ 18 years and ≤ 39 years of age at registration. Patient must have a histologically confirmed diagnosis of primary cancer of any…. Goal: The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eastern Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies is being studied. Conditions: Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 3. Histologically confirmed diagnosis of any of the following: • Gastric or…. Goal: The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anwaar Saeed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer • Eligibility: Inclusion Criteria 1. Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC). 2. Locally advanced unresectable or metastatic BTC…. Goal: The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jazz Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Institutional Registry of Rare Diseases is being studied. Conditions: Rare Diseases, Amyloidosis, Sarcoidosis +23 • Eligibility: Inclusion Criteria: * Clinical and/or molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn…. Goal: The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD). Moreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hospital Italiano de Buenos Aires.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is being studied. Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult +18 • Eligibility: Inclusion Criteria: * Patient must be ≥ 18yrs of age. * Patient must have the ability to understand, and the willingness to sign, a written informed consent form.…. Goal: This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer Metastatic • Eligibility: Inclusion Criteria: * Signed written Informed Consent. * Male and female subjects aged greater than or equal to18 years. * Eastern Cooperative Oncology Group (ECOG) Performance Score 0…. Goal: This study aims to determine the safety and best response of treatment with CNA3103 (Leucine-rich repeat-containing G protein-coupled receptor 5 \[LGR5\]-targeted, Autologous Chimeric Antigen Receptor (CAR) -T Cells), for participants with Metastatic Colorectal Cancer. Participants may undergo a pre-screening biopsy procedure to determine expression of LGR5. Phase/Status/Sponsor: Unknown phase; RECRUITING; Carina Biotech Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Gallium-68 FAPI PET/CT to see if it improves detection, staging, and restaging of biliary tract cancers compared with the standard FDG PET/CT. It is for adults 18 and older with suspected or confirmed biliary cancers, including gallbladder cancer, cholangiocarcinoma, or suspected recurrence after treatment. The study will assess how well FAPI detects primary tumors, lymph node involvement, and metastases and whether it changes clinical decisions or reduces the need for invasive procedures. Participants must give informed consent, and those with a concurrent malignancy are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling is being studied. Conditions: Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM), Circulating Tumor DNA (ctDNA) • Eligibility: Inclusion Criteria: * Age ≥ 21 years * A history of histologically confirmed (metastatic) colorectal adenocarcinoma * Currently diagnosed with (progressive) colorectal liver metastases (CRLM) * Signed informed…. Goal: The goal of this observational study is to investigate whether circulating tumor-derived DNA (ctDNA) can be reliably detected and analyzed in blood obtained through automated capillary sampling in adult patients (≥21 years) with colorectal liver metastases (CRLM). The main question it aims to answer is: * Can ctDNA be detected in small volumes of capillary blood collected using an automated sampling device? Phase/Status/Sponsor: Unknown phase; RECRUITING; Erasmus Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling is being studied. Conditions: Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult +5 • Eligibility: Phase 1 (Common Cancer Early Detection - CCANED) Inclusion Criteria: * Age: Adults aged 40 years or older. * Confirmed diagnosis of one of the following common cancers:…. Goal: The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Javier Toledo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Target-specific immunoPET Imaging of Digestive System Carcinoma is being studied. Conditions: Malignancy, Digestive Cancer, Digestive System Neoplasm +12 • Eligibility: Inclusion Criteria: 1. Aged 18-75 years old and of either sex； 2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging; 3.…. Goal: The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated. Phase/Status/Sponsor: Unknown phase; RECRUITING; RenJi Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Collection of Blood From Patients With Cancer is being studied. Conditions: Prostate Cancer, Breast Cancer, Colon Cancer +2 • Eligibility: * INCLUSION CRITERIA: Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible. Performance status of ECOG 0, 1, 2,…. Goal: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer is being studied. Conditions: Metastatic Colon Cancer, Stage III Colon Cancer • Eligibility: Inclusion Criteria: * Participants must have histologically confirmed resected Stage III adenocarcinoma of the colon. Any T \[Tx, T1, T2, T3, or T4-\], N1-2M0. * Participants must have…. Goal: This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests the drug tivozanib for biliary tract cancers (cholangiocarcinoma and gallbladder cancer) in adults who have already had chemotherapy, to find the safest and most effective dose and to learn its overall response rate. It is open-label, non-randomized, and carried out at a single center, using 28-day treatment cycles (3 weeks on, 1 week off) with efficacy checked every 8 weeks. Eligible participants are adults 18 or older with biliary tract cancer not removable by surgery who have had prior first-line chemotherapy and have adequate organ function. Key exclusions include prior tivozanib use, pregnancy, and significant cardiovascular disease or uncontrolled hypertension.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers is being studied. Conditions: Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers +3 • Eligibility: * INCLUSION CRITERIA: * Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck…. Goal: Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests amivantamab plus FOLFIRI versus cetuximab/bevacizumab plus FOLFIRI in people with KRAS/NRAS and BRAF wild-type colorectal cancer who have previously received chemotherapy. - It aims to learn whether the amivantamab combination improves progression-free survival and overall survival compared with the cetuximab/bevacizumab combination. - Eligible participants have recurrent, unresectable, or metastatic colorectal cancer with confirmed KRAS/NRAS and BRAF wild-type status, have had at least one prior systemic therapy for metastatic disease, and have ECOG 0–1. - Key exclusions include preexisting interstitial lung disease/pneumonitis, allergies to study drugs, prior exposure to irinotecan or EGFR/MET inhibitors, HER2-positive tumors, or another active malignancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This multicenter, open-label, single-group trial tests photodynamic therapy using Cosiporfin Sodium together with gemcitabine and cisplatin (GC) for people with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma that cannot be operated on. - It aims to preliminarily measure efficacy, focusing on the 6-month overall survival rate, and to assess safety and tolerability of the PDT plus GC treatment in patients with biliary obstruction. - Eligible participants are adults with histologically confirmed disease, inoperable or unwilling to have surgery, with biliary obstruction and at least one measurable lesion outside the bile ducts, plus good performance status and adequate organ function. - Key exclusions include ampullary cancer, brain metastases, major liver tumor burden (>50%), prior exposure to photosensitizers or PDT, prior systemic therapy in the recurrent/metastatic setting, unremovable biliary stents, active infections, and other conditions that could interfere with treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) is being studied. Conditions: Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer • Eligibility: Inclusion Criteria: 1. Patients with cytologically or histologically confirmed BTC by AJCC version 8. 2. Patients must have late stage (locally advanced, recurrent or metastatic) BTC. Patients must…. Goal: This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nataliya Uboha.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors is being studied. Conditions: Cervical Cancer, Breast Cancer, Colon Cancer +4 • Eligibility: 1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate…. Goal: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Orano Med LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of Emotional Disorders on Response to Immune Checkpoint Inhibitor Therapy in Liver Cancer is being studied. Conditions: Liver Cancer, Emotional Disorder • Eligibility: Inclusion Criteria: * Age between 18 and 75 years, inclusive, regardless of gender. * Presence of at least one radiologically measurable lesion according to the Response Evaluation Criteria…. Goal: Hepatocellular carcinoma (HCC) carries a poor prognosis, with limited efficacy from current therapies including immune checkpoint inhibitors (ICIs). Concurrently, emotional distress (ED) is highly prevalent in cancer patients and is implicated in tumor progression via neuroendocrine-immune axis dysregulation (e.g., HPA axis activation, immunosuppressive TME). Phase/Status/Sponsor: Unknown phase; RECRUITING; Tongji Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether objectively measured physical activity, collected with wearables, is linked to ECOG performance status and overall survival in adults with advanced cancer. - It is for adults with various advanced cancers who live in the Houston area and can participate in English. - The trial also looks at whether wireless data collection and transfer into the CYCORE system is feasible and acceptable in real-world cancer care. - Key exclusions include recent major surgery, certain cognitive or unstable heart/lung conditions, lack of home internet/WiFi, pregnancy, pacemakers, or current enrollment in conflicting protocols.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Colorectal Cancer AJCC v8 • Eligibility: Inclusion Criteria: * Age \>= 18 years * Biopsy proven colorectal cancer with peritoneal metastasis. Patients with extraperitoneal metastases will not be eligible. Patients with involvement of intra-abdominal…. Goal: This phase I trial tests the safety, side effects, and best dose of intraperitoneal oxaliplatin and fluorouracil in treating patients with colorectal cancer that has spread to the peritoneal cavity (peritoneal metastasis). Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. Phase/Status/Sponsor: Unknown phase; RECRUITING; Arjun Mittra.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intravital Microscopy in Human Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm +20 • Eligibility: Inclusion Criteria: * Age ≥ 18 years of age * Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2 * Measurable tumor by direct visualization requiring surgical resection…. Goal: This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body is being studied. Conditions: Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors • Eligibility: Key Inclusion Criteria: Dose escalation cohorts: 1. Histologically or cytologically confirmed diagnosis of solid malignancy (locally advanced or metastatic) with confirmed progression on standard-of-care therapy 2. Participants are…. Goal: This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether ivonescimab is more effective than the standard second‑line chemotherapy FOLFOX for adults with advanced biliary tract cancer who progressed after first‑line treatment and who participated in SAFIR-ABC10. Participants are randomized 2:1 to receive ivonescimab every 3 weeks or FOLFOX, with the ivonescimab arm limited to up to 34 cycles. Treatments continue until disease progression or until the study limits are reached, and tumor responses are checked by imaging roughly every 6 weeks using RECIST v1.1. Key exclusions include contraindication to ivonescimab, unresolved toxicities from prior therapy, and conditions such as active HIV or TB, active autoimmune disease requiring systemic treatment, pregnancy, or recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CRC Screening in Unscreened Individuals 45-54 is being studied. Conditions: Colorectal Cancer Screening • Eligibility: PATIENTS Inclusion Criteria: * Individuals aged 45-54 * Individuals who are patients at the health center * Individuals that are willing and able to give verbal/written consent Exclusion…. Goal: The goal of this observational study is to understand the barriers and facilitators to completing colorectal cancer screening from the patient and community health center staff perspective. The main question it aims to answer is to identify system-level determinants of colorectal cancer screening in individuals aged 45 to 54. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment is being studied. Conditions: Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms +1 • Eligibility: Inclusion Criteria: * Diagnosis of cancer in either the adjuvant or metastatic setting requiring initial therapy with 5-FU or Capecitabine. * DPYD testing performed by a CLIA-certified laboratory…. Goal: To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm. Phase/Status/Sponsor: Unknown phase; RECRUITING; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma. is being studied. Conditions: Intrahepatic Cholangiocarcinoma (Icc) • Eligibility: Inclusion Criteria: * Histologically confirmed ICC (clinical stage I-III). * Undergoing curative-intent hepatectomy. * Availability of preoperative pasma or serum sample (≥200 µL). * Standard staging imaging completed…. Goal: Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to detect occult metastasis preoperatively in patients with resectable ICC. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes is being studied. Conditions: Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms +76 • Eligibility: Inclusion Criteria: * Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study…. Goal: Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Phase/Status/Sponsor: Unknown phase; RECRUITING; Cedars-Sinai Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether contrast-enhanced ultrasound (CEUS) can be used to evaluate how hepatocellular carcinoma (HCC) responds after transarterial radioembolization (TARE). - It is for adults with treatment-naïve HCC who are scheduled to undergo TARE. - The study will compare CEUS results with standard CT or MRI at about 1–2 months and 4–6 months post-TARE to see if CEUS can detect viable tumor earlier. - About 30 patients will be enrolled over 18 months across Jefferson Health sites, with at least 6 months of follow-up. - Exclusion criteria include medical instability or serious illness and known sensitivities to the ultrasound contrast agents Lumason or Sonazoid.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC is being studied. Conditions: Metastatic Colorectal Cancer (mCRC) • Eligibility: Inclusion Criteria: 1. Male or female subjects age ≥ 18 years with a history of treated colorectal cancer with unresectable metastases of the primary colorectal cancer to other…. Goal: This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. The main questions this study aims to answer are: 1. Phase/Status/Sponsor: Unknown phase; RECRUITING; CytoDyn, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II) is being studied. Conditions: Colorectal Cancer, Colorectal Polyp, Colorectal Adenoma +3 • Eligibility: Inclusion Criteria: \- Patients with a previously detected polyp in the rectum referred for resection. These criteria will ensure the probability of finding polyps during the explorations. All…. Goal: The study involves the planned use of a new microwave-based device during colonoscopy procedures in 50 patients to assess the performance and safety of its use for detection of colorectal polyps and lack of normal clinical practice modification. The device is a final design version, which has been previously tested in several preclinical studies (including phantom studies, an ex vivo study with human tissues, and an in vivo study with porcine model) and in a pilot study in humans (NCT05477836) Phase/Status/Sponsor: Unknown phase; RECRUITING; MiWEndo Solutions S.L..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer is being studied. Conditions: BRAF V600 Colorectal Cancer • Eligibility: Inclusion Criteria: * Age ≥18 years and ≤75 years * Histologically confirmed metastatic colorectal adenocarcinoma * BRAF V600E mutation confirmed by tissue pathology or ctDNA testing (PCR or…. Goal: The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The main questions it aims to answer are: Does IB-FOLFIRI improve clinical outcomes compared with historical outcomes in this population? Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This randomized, multicenter trial tests UI-EWD (Nexpowder) hemostatic powder as the initial treatment, compared to conventional endoscopic therapies for nonvariceal upper GI bleeding. - It is for adults 22 years and older who have acute overt upper GI bleeding seen on endoscopy from ulcers with active bleeding or a visible vessel, tumors with bleeding, Dieulafoy lesions, or Mallory-Weiss tears. - The study aims to determine whether UI-EWD is noninferior to traditional therapy in stopping bleeding and reducing rebleeding when used first. - Key exclusions include pregnancy or nursing, inability to consent, recent endoscopic hemostatic treatment within 30 days, triple antithrombotic therapy, very low platelet count (<50 x 10^9/L), high INR (>3.5), and endoscopy not performed within 36 hours.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests the molecular and genetic basis of pediatric liver cancer by analyzing tumor tissue, blood, and saliva from affected children and their biological parents and siblings. It is for children under 21 who have had a liver tumor (benign or malignant) and their families. Researchers aim to learn how gene defects and gene function influence how these cancers develop and behave, to improve classification and future treatments. Exclusions include no prior or current treatment for a childhood liver tumor, and non-biological guardians or non-biological siblings.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer +1 • Eligibility: Inclusion Criteria Patients who meet ALL the following inclusion criteria will be eligible to participate in the study: 1. ≥18 years of age. 2. Histologically confirmed, locally advanced,…. Goal: The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work. Phase/Status/Sponsor: Unknown phase; RECRUITING; JiaRay Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer is being studied. Conditions: Safety and Efficacy • Eligibility: Inclusion criteria: 1. Patients over 18 years old 2. Patients can remain in a stationary position on the treatment bed for 1-1.5 hours 3. ECOG score 0-1 4.…. Goal: In this phase I single-arm clinical study, 20 patients with T4 unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX. The study will assess patients' surgical R0 resection rate, pCR or cCR rate, PFS, OS, and related adverse effects of treatment, aiming to explore the feasibility, safety, and efficacy of MR-Linac in the treatment of unresectable locally advanced colon cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sichuan Cancer Hospital and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FITting Non-invasive Tests in Lynch Syndrome Surveillance is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Have a diagnosis of LS with a confirmed pathogenic variant in MLH1, MSH2, MSH6, PMS2 or EPCAM genes. * Aged 20 - 75 years (for…. Goal: The purpose of this clinical study is to evaluate the accuracy of the fecal immunochemical test (FIT) in comparison to colonoscopy in patients with Lynch Syndrome (LS) who are undergoing colonoscopy surveillance. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * An adult 18 to 100 years of age, * Able to read English or Spanish at least an eighth-grade level, * From a racial/ethnic background…. Goal: The purpose of this study is to pilot test and evaluate an existing tailored ALEX (Agent Leveraging Empathy for eXams) Research Portal to navigate Black and Hispanic adult cancer patients and their family members through referral to cancer clinical trials. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a 3D biliary tract reconstruction tool and an AI algorithm to help endoscopists perform ERCP by creating 3D models from MRCP and CT scans. - It is for adults with biliary strictures who are treated with ERCP at Saint Antoine Hospital or Henri Mondor Hospital. - The study is retrospective and uses imaging data collected during routine care to develop and validate the software. - The goal is to see if the 3D models improve visualization and navigation during ERCP, with performance assessed by image-quality metrics and localization error, and without changing patient management. - Exclusion: patients who do not consent to reuse their data for research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study on the Efficacy of the Metaverse Lifestyle Health Education Model Based on the Transtheoretical Model for Improving Quality of Life and Modifying Lifestyle in Colorectal Cancer Survivors is being studied. Conditions: Colorectal Neoplasms, Cancer Survivors • Eligibility: Inclusion Criteria: 1. Patients with first diagnosed colorectal cancer who have undergone radical surgical treatment 2. Aged ≥18 years old and non-pregnant 3. Have basic communication, reading and…. Goal: Colorectal cancer is a globally prevalent malignant tumor. Postoperative patients often face physical discomfort, psychological stress, and lack of healthy lifestyles. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qu Shen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures is being studied. Conditions: Painless Gastrointestinal Endoscopy • Eligibility: Inclusion Criteria: * Age ≥18 years and ≤75 years, regardless of sex; * Patients scheduled to undergo painless gastrointestinal endoscopy examination or endoscopic surgery, which must include upper…. Goal: Gastrointestinal endoscopy procedures, including upper gastrointestinal endoscopy and colorectal endoscopy, represent a fundamental and important method for examining and managing digestive tract diseases, with both diagnostic and therapeutic applications. They are also utilized as effective tools for surveillance of gastrointestinal tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Jiao Tong University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests LY4066434, a pan-KRAS inhibitor, in people with KRAS-mutant solid tumors. - It includes patients whose tumors have specific KRAS mutations (G12C, G12D, G12V, G12A, G12S, or G13D) and who have locally advanced, unresectable, or metastatic cancer with measurable disease. - The trial will evaluate LY4066434 alone or with other treatments to see if it is safe and tolerable, using two parts: monotherapy dose escalation and dose optimization, over up to about 5 years. - Key exclusions include active CNS metastases, significant cardiovascular disease, active hepatitis B or C or untreated HIV, other active cancers, and uncontrolled infections.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Effect of Preoperative Training With Virtual Reality on Anxiety, Readiness for Surgery and Recovery Process of Patients in Colorectal Cancer Surgery is being studied. Conditions: Anxiety, Surgical Preparation, and Recovery Process in Colorectal Cancer Surgery • Eligibility: Inclusion Criteria: Agreement to participate in the study, Ability to read and write in Turkish, Being conscious and communicative. Exclusion Criteria: Those with any psychiatric illness, Those diagnosed…. Goal: The aim of the study is to determine the effect of The Effect of Preoperative Training with Virtual Reality on Anxiety, Readiness for Surgery and Recovery Process of Patients in Colorectal Cancer Surgery. Research Hypotheses In patients undergoing colorectal surgery: H1 The comfort level of patients who received preoperative training using virtual reality is higher than that of patients who received training using written brochures and the control group. Phase/Status/Sponsor: Unknown phase; RECRUITING; Istanbul University - Cerrahpasa.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. is being studied. Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor. ECOG PS 0 or 1 * Presence of at least 1 measurable…. Goal: The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. Phase/Status/Sponsor: Unknown phase; RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria for Cohort A and B: * Age ≥70 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0 -2 * Have histologically proven localized or locally…. Goal: The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater considered poor candidates for surgery. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This early-phase trial tests a treatment for unresectable liver cancer using a patient’s own dendritic cells plus the Prevnar vaccine, given with immune checkpoint inhibitors after high-dose external beam radiotherapy. - It includes adults with hepatocellular carcinoma or intrahepatic cholangiocarcinoma that cannot be removed and have been treated with EBRT, with dendritic cells injected into the tumor and vaccines given alongside atezolizumab plus bevacizumab or atezolizumab plus tiragolumab. - The study aims to evaluate safety and tolerability and to estimate progression-free survival and other outcomes to see if this approach can stimulate the immune system and slow the cancer, compared with historical data. - Key exclusions include pregnancy or breastfeeding, immunocompromised status (including HIV), active infection or uncontrolled illness, autoimmune disease (with some exceptions), inability to stop anticoagulants for injections, and advanced liver disease (Child-Pugh B/C) or prior immune-modulating therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Comprehensive Care of Cancer Patients is being studied. Conditions: Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer • Eligibility: Inclusion Criteria: * For patients: 1) new diagnosis or within three months of treatment initiation for early-stage breast (I-IIIB), GI (Stage I-III), or hematologic (Stage I-III) cancer 2)…. Goal: Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support. Nearly 70% of survivors have at least one comorbid chronic condition in addition to cancer, which complicates the delivery of quality cancer care. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System is being studied. Conditions: Cancer, Cancer Central Nervous System, Cancer Thoracic +5 • Eligibility: Inclusion Criteria: * Able to comprehend and be willing to sign an informed consent form (ICF). * Diagnosis of local, loco-regionally advanced, or metastatic malignancy for whom radiotherapy…. Goal: The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the use of the RefleXion system to deliver intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), or SCINTIX Biology-guided radiotherapy (BgRT) in standard of care (SOC) use in the treatment of local,loco-regionally advanced, and oligometastatic malignancies. In addition, patient costs and charges will be analyzed to quantify the health economic impact of this modality. Phase/Status/Sponsor: Unknown phase; RECRUITING; RefleXion Medical.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a two-step, neoadjuvant treatment for intrahepatic cholangiocarcinoma (ICC): 12 weeks of capecitabine plus Selective Internal Radiation Therapy (SIRT) with Yttrium-90, given before surgery. - The goal is to see if this approach can shrink or downstage tumors so surgery is more feasible and potentially more successful, compared with upfront surgery. - It is for adults with histologically confirmed ICC that surgeons consider resectable but at high risk for close margins; key exclusions include severe liver disease or poor organ function, prior ICC chemotherapy, contraindication to hepatic artery catheterization, pregnant status, and other active cancers. - Participants are randomly assigned to the experimental neoadjuvant treatment or to the standard approach of immediate surgery, with long-term follow-up to compare outcomes.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a French multicenter, retrospective, observational study that is currently recruiting to study rare primary liver cancers. It includes adults 18 and older with histologically confirmed hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, or hepatic angiosarcoma diagnosed after January 1, 2018. The study aims to describe clinical, histological and radiological features, collect tumor tissue and blood, and evaluate how treatments used in real-world care have performed to help determine the best sequencing of therapies. Key exclusions are lack of social security and no access to tumor tissue; living participants must consent to research for ancillary studies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer is being studied. Conditions: Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic • Eligibility: Inclusion Criteria 1. Adults (aged 18 or more at enrollment) 2. Histologically or cytologically proven pancreatic or colorectal cancer. Histologies may include listing of adenocarcinoma, poorly differentiated carcinoma,…. Goal: Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Phase/Status/Sponsor: Unknown phase; RECRUITING; HealthPartners Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer is being studied. Conditions: Liver Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer +2 • Eligibility: The following criteria must be met for subjects to be considered for the trial. Additional exclusion criteria must be met for subjects interested in the HepQuant subset of…. Goal: This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases regardless of primary histology, that are undergoing photon radiation either in the de-novo or re-irradiation setting. The goal of this study is to prospectively evaluate the feasibility of using quantitative multiparametric MRI to monitor liver function at baseline and following liver radiation therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Montefiore Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Role of Photon Counting CT in Detecting Liver Metastatis From Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * adult (\>18 years) * non- biopsy-proven colon/colorectal carcinoma * CT performed on a PCD-CT * MRI with multiparametric protocol and hepatospecific contrast media Exclusion Criteria:…. Goal: Colorectal cancer is the first leading cause of cancer death in men and second in women. Its incidence rates also increased by 1%-2% annually in young adults (ages \<55 years). Phase/Status/Sponsor: Unknown phase; RECRUITING; IRCCS San Raffaele.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of LNCB74 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer +3 • Eligibility: Inclusion Criteria: 1. The participant provides written informed consent 2. ≥ 18 years of age on day of signing informed consent. 3. Participant with histologically or cytologically confirmed…. Goal: This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; NextCure, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of GC203 TIL in Advanced Malignant Solid Tumors is being studied. Conditions: Solid Tumor, Gynecologic Cancer, Breast Cancer +2 • Eligibility: Inclusion Criteria: * 1\. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures. 2\. Patients must be ≥18…. Goal: A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Juncell Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer is being studied. Conditions: Colorectal Cancer (CRC) • Eligibility: Inclusion Criteria: 1. Voluntarily participate in this trial, sign the informed consent form. 2. Advanced colorectal cancer patients who have either failed standard treatment, experienced intolerable toxicity, or…. Goal: This study is a single-arm, single-center investigator-initiated trial (IIT) designed to evaluate the safety and preliminary efficacy of CDH17/GUCY2C CAR-T cell therapy in patients with advanced colorectal cancer, as well as to assess its pharmacodynamic (PD) and pharmacokinetic (PK) profiles. Phase/Status/Sponsor: Unknown phase; RECRUITING; Guangzhou Bio-gene Technology Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * Life expectancy \>= 12 weeks per investigator assessment. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 during the screening period…. Goal: Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused telisotuzumab adizutecan to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC). Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients is being studied. Conditions: Colorectal Carcinoma, Lynch Syndrome • Eligibility: Inclusion Criteria: * Patients at least 18 years of age * Individuals diagnosed with Lynch syndrome (mutation in MLH1, MSH2, MSH6, PMS2, EPCAM) or suspected Lynch syndrome or…. Goal: This study collects blood and stool samples from patients with suspected or diagnosed Lynch syndrome to evaluate a deoxyribonucleic acid (DNA) screening technique for the detection of colorectal cancer in Lynch syndrome patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics is being studied. Conditions: Breast Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Any participant over 18 years old who self-identifies as Black or African-American and signs an informed consent form, also referred to as the 'Permission to…. Goal: To identify Black individuals who are eligible for genetic testing through trusted community organizations, and to connect Black individuals and their families to genetic testing and counseling so that they can know their cancer risk and how to decrease it. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Has histological confirmation of colorectal cancer 2. Received post-R0 resection of stages II, III, or IV colorectal cancer and has completed all planned curative intent…. Goal: To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a streamlined approach to transarterial radioembolization (TARE) for liver cancer, using SIR-Spheres in a same-day, single-session procedure without full pre-procedural nuclear imaging for eligible patients. - It is for adults with metastatic liver cancer or cholangiocarcinoma whose largest tumor is 7 cm or smaller, up to five tumors, enough healthy liver tissue, good liver function (Child-Pugh A), and good performance status (ECOG ≤1). - The study aims to determine if this faster method can be safely delivered, with predefined dosing rules (lung shunt assumed 5%, lung dose ≤10 Gy) and post-treatment dosimetry the next day, followed for one year. - Exclusions include hepatic vein invasion or hepatic vein enhancement, dysmorphic intratumoral vessels >3 mm, TIPS, major portal vein issues, biliary stents, allergy to contrast, or other factors that could raise the risk of radiation pneumonitis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a first-line treatment for unresectable intrahepatic cholangiocarcinoma using FOLFOX-based hepatic arterial infusion chemotherapy with donafenib and pucotenlimab. - It is a prospective, open-label, single-arm phase II study and is not yet recruiting. - The primary goal is to measure the objective response rate, with secondary goals including progression-free survival, overall survival, disease control rate, and safety. - Eligible participants are adults up to 75 years old; key exclusions include prior anti-PD-1/PD-L1 therapy, active CNS metastases, autoimmune disease requiring systemic treatment, active infection, HBV DNA > 2000 IU/mL, HIV, syphilis, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Precision Physical Exercise for Personalized Onco-Hematology. is being studied. Conditions: Hematologic Cancer, Colon Cancer, Breast Cancer +3 • Eligibility: Inclusión criteria: * Adult patients (≥18 years), capable of signing the informed consent and willing to participate in the study. * Performance status (ECOG) 0-2. * Specific inclusion…. Goal: Physical exercise, particularly strength training, has become an effective strategy to improve physical function, muscle mass, and quality of life in cancer patients. However, the biological mechanisms underlying these benefits remain poorly understood, especially during active treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of Salamanca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors is being studied. Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) • Eligibility: Key Inclusion Criteria: mCRPC cohorts (men): 1. Men with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma. 2. PSA value at screening ≥4…. Goal: The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) +6 • Eligibility: Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are…. Goal: The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC. Phase/Status/Sponsor: Unknown phase; RECRUITING; ITM Oncologics GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests PSMA-targeted imaging and PSMA expression in biopsy tissue for patients with newly diagnosed gastroenterologic tumors. It aims to see if PSMA-PET can detect more disease sites than standard imaging and whether the PSMA signal can predict outcomes under guideline-based treatment. Eligible participants are adults with newly diagnosed GET before starting guideline-compatible anti-tumor therapy, with available tumor tissue and the ability to consent and follow up. Exclusions include curative-intent treatment, insufficient tumor tissue, history of other cancers, pregnancy or breastfeeding, contraindications to PET/CT, and men with prostate cancer. The study is sponsored by Würzburg University Hospital and is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors is being studied. Conditions: Esophageal Cancer, Gastric Cancer, Pancreatic Cancer +2 • Eligibility: Inclusion Criteria: 1. Voluntarily sign the informed consent and follow the requirements of the protocol; 2. No gender limit; 3. Age: ≥18 years old and ≤75 years old…. Goal: This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expression gastrointestinal cancer and other solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sichuan Baili Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors is being studied. Conditions: Solid Tumours, Sarcoma, HNSCC +9 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed disease, locally advanced or metastatic: For Phase 1a: Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are…. Goal: The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; Epkin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories is being studied. Conditions: Bile Duct Adenocarcinoma, Bile Duct Carcinoma • Eligibility: Inclusion Criteria: 1. Provision to sign and date the consent form; 2. Adult patients ≥ 21 years old; 3. Any patient who is required to undergo endoscopic retrograde…. Goal: This study plans to enroll up to 75 research subject who have a biliary disorder such as bile duct stones or intermediate biliary strictures. The purpose of this research is to assess whether the Dragonfly™ Pancreaticobiliary Scope functioned as intended in combination with the commercially available accessories during your scheduled endoscopy procedure. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Colorado, Denver.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Age 18-75 years, regardless of gender. * Pathologically confirmed rectal adenocarcinoma. * Tumor located ≤10 cm from the anal verge. * Baseline stage T3-4 and/or…. Goal: This randomized phase II trial evaluates the efficacy of long-course chemoradiotherapy (50Gy/25Fx + capecitabine) versus short-course radiotherapy (25Gy/5Fx) combined with CAPOX（Capecitabine and Oxaliplatin）, PD-1 inhibitor (serplulimab), and COX-2 inhibitor (celecoxib) in MSS（MicroSatellite Stable） locally advanced rectal cancer, with primary endpoint of complete response rate (pCR+cCR)（Complete Remission） and secondary endpoints including anal preservation rate and 3-year survival outcomes, aiming to elucidate the immunomodulatory effects of triple therapy on tumor microenvironment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer is being studied. Conditions: Unresectable Colorectal Neoplasm Metastasis • Eligibility: Inclusion Criteria: * Patients with histologically or cytologically diagnosed colorectal cancer * Patients who are refractory or intolerant to standard treatment for unresectable advanced or recurrent colorectal cancer…. Goal: Tankyrase, the fifth and sixth members of the poly(ADP-ribose) polymerase (PARP) family (PARP-5a/b), is responsible for poly(ADP-ribosyl)ation (PARylation), and was originally identified as a factor that promotes the function of telomerase, an enzyme that elongates telomeres. Subsequently, it was reported that tankyrase enhances Wnt/beta-catenin signaling by PARylation and subsequent degradation of AXIN, a negative regulator of Wnt/beta-catenin signaling, suggesting that tankyrase inhibitors may be a new treatment for colorectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eiji Shinozaki.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer is being studied. Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer • Eligibility: Inclusion Criteria: * Patient must be \>= 18 years of age * Patient must have a histologically confirmed diagnosis of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) at the local laboratory…. Goal: This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with liver cancer that cannot be removed by surgery (unresectable) or that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the combination of nivolumab and ipilimumab in adults with rare cancers to see if it can shrink tumors or slow their growth. - It includes many different rare tumor types in separate groups, plus a PD-L1–amplified cohort that uses nivolumab alone, and it measures how often tumors respond using standard criteria. - The trial also looks at safety, overall survival, and progression-free survival across cohorts. - Eligible participants must have progressed after prior therapy and generally cannot have active brain metastases or uncontrolled autoimmune disease; some cohorts have additional specific requirements or exclusions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer is being studied. Conditions: Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8 • Eligibility: * Stage II-III colorectal cancer patients scheduled to receive oxaliplatin 510 mg/m\^2 (cumulative dose) over 12 weeks as a component of adjuvant leucovorin calcium (calcium folinate), 5-fluorouracil and…. Goal: This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer is being studied. Conditions: Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 +2 • Eligibility: Inclusion Criteria: * PRE-REGISTRATION (STEP 0) ELIGIBILITY CRITERIA: * BRAF V600 mutational status may be determined either locally or by central testing. This testing is mandatory prior to…. Goal: This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

First in Human Study of QLS5316 in Solid Tumors is being studied. Conditions: Solid Tumors, Colorectal Cancer, Gastric Cancer or Gastroesophageal Junction Adenocarcinoma +2 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 3. Life expectancy ≥ 3 months; 4. Measurable disease per RECIST v1.1…. Goal: This is a first-in-human (FIH) Phase I, multi-center, open-label, study of QLS5316, in patients with advanced solid tumors. The study aim to evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of QLS5316 as monotherapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qilu Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) is being studied. Conditions: Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC) +1 • Eligibility: Inclusion Criteria: * Clinical diagnosis of gastric cancer and colorectal cancer * Aged 18 to 75 years: * Able to sign a written informed consent form and understand…. Goal: This study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy/radiotherapy for patients with HER2-positive locally advanced or metastatic gastrointestinal tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tao Zhang.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluating the Efficacy of the eNav Toolkit to Improve Colorectal Cancer Screening is being studied. Conditions: Colorectal Cancer Screening • Eligibility: Inclusion Criteria: * Patient treated at the Institute for Family Health (IFH) * Patient 45 to 75 years old * English or Spanish speaking * Able to provide…. Goal: The purpose of this research study is to evaluate the efficacy of a digital navigation tool, called the eNav to improve colorectal cancer screening uptake among patients treated at federally qualified health centers (FQHC)s. The digital navigation tool includes a website and text messaging support. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Icahn School of Medicine at Mount Sinai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Have a full understanding of this study and voluntarily sign the informed consent form; 2. Aged 18 - 75 years; 3. Patients must be pathologically…. Goal: The goal of this clinical trial is to explore the preliminary efficacy and tolerability of Aipalolitovorelizumab (QL1706) in combination with fruquintinib for the treatment of metastatic colorectal cancer patients with immunodominant pMMR/MSS type who have failed second-line or above treatment. It is an open-label, single-arm, single-center phase II trial. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Harbin Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Colorectal Cancer Screening in the Homeless is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Homeless persons aged 45 - 75 years old, with no up-to-date colorectal cancer screening defined as: 1) no colonoscopy in the past 10 years, or…. Goal: This study is designed to assess the effect of implementing a text messaging strategy for colorectal cancer screening among homeless persons aged 45-75 years, who are not up to date on colorectal cancer screening, in shelter clinics in NYC. This mixed-methods study uses a randomized clinical trial design and semi-structured interviews. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; George Washington University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer (BTC) • Eligibility: Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled in this study: 1. No gender restriction, age ≥18 years, and expected survival ≥3 months;…. Goal: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the impact of Yueju Pill on quality of life and treatment efficacy in patients with advanced biliary tract cancer (BTC) receiving standard therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) is being studied. Conditions: Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy +1 • Eligibility: Inclusion Criteria: * • Voluntarily signs a written informed consent form. * Aged between 18 and 75 years at the time of enrollment. * Eastern Cooperative Oncology Group…. Goal: Most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) and respond poorly to PD-1 inhibitors. Radiotherapy can enhance tumor antigen release and improve responsiveness to PD-1 blockade in MSS/pMMR rectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sixth Affiliated Hospital, Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: Interventional Cohort 1. Adults (≥21 years) scheduled for elective low anterior resection (by any surgical technique), due to colorectal cancer 2. Expected anastomosis within 10 cm…. Goal: Purpose: To evaluate the effect of xBar system utilization on clinical outcomes during recovery following colorectal surgery. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Exero Medical Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study is a prospective randomized trial comparing two ERCP cannulation techniques: Precut needle-knife precut versus the Intentional Double Guidewire Technique. It targets adults with biliary obstruction who need ERCP and have a native papilla with difficult cannulation (per ESGE 5-5-2). The goal is to learn which method provides better biliary access and has a safer profile during difficult cannulation. Eligible participants are adults over 18 with benign or malignant obstruction and no prior sphincterotomy; key exclusions include ampullary mass, surgically altered anatomy, uncorrectable coagulopathy, or acute pancreatitis before ERCP.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors is being studied. Conditions: HNSCC, Melanoma, Gynecologic Cancer +3 • Eligibility: Inclusion Criteria * Participants must have signed and dated a current IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. Patients must have the…. Goal: The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies. The TIL selection process is based on evidence showing that CD8+ TIL which co-express both CD39 and CD103 harbor the bulk of tumor-reactivity and that the remaining CD8 TIL is mainly composed of non-tumor reactive bystander cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AgonOx, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study is being studied. Conditions: Colorectal Cancer, Stoma - Ileostomy • Eligibility: Inclusion Criteria: A subject meeting all of the following criteria will be considered for participation in the study: 1. Adult patients (22 years of age or older) 2.…. Goal: Colorectal cancer is the third most common malignancy worldwide and the second most common in the US. It is the second leading cause of cancer death worldwide, with 1.8 million new cases and 862,000 deaths per year. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; SafeHeal Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. is being studied. Conditions: Biliary Tract or Colorectal Cancer With Her2-positive/Mutated • Eligibility: Inclusion Criteria: 1. Metastatic and/or unresectable advanced colorectal adenocarcinoma, or locally advanced, recurrent, metastatic and/or unresectable advanced biliary tract carcinoma 2. HER2 positive or HER2 gene mutation; 3.…. Goal: To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Pharmaceuticals Holding Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer (CRC), Antineoplastic Agents, Immunological, VEGFR-TKI • Eligibility: Inclusion Criteria: * Patients aged 18 and over. * Histologically confirmed colorectal adenocarcinoma with locally advanced disease and/or unresectable metastasis(es) receiving treatment with fruquintinib under i) compassionate/early access…. Goal: The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Federation Francophone de Cancerologie Digestive.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding peginterferon alfa-2b to standard nucleos(t)ide analogue therapy can reduce recurrence of HBV-related liver cancer after radical treatment. - It is for adults aged 18-70 who are HBV surface antigen positive and have hepatocellular carcinoma treated with surgery or ablation, with good liver function (BCLC 0-A, Child-Pugh A). - The study is single-center, non-randomized, open-label, comparing NAs alone versus NAs plus peginterferon alfa-2b to see if it lowers the 3-year recurrence rate and may improve cure. - Participants will undergo regular imaging and blood tests every few months to monitor recurrence and safety. - Key exclusions include prior systemic cancer treatments, other active cancers, allergy to interferon, severe liver or kidney disease, autoimmune disease, pregnancy, or participation in other trials.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer is being studied. Conditions: Stage II/III Colon Cancer, Bowel Cancer • Eligibility: Inclusion Criteria: * Aged 18 or over * Histologically proven single primary site colorectal adenocarcinoma or high grade dysplasia plus unequivocal radiological evidence of invasive cancer * Stage…. Goal: TThis study evaluates the safety and effectiveness of pre-operative artesunate, given orally once a day for 14 days prior to surgery, in patients with Stage II/III colorectal cancer. Artesunate is an established antimalarial drug with an excellent safety profile. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Metanoic Health Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests pimitespib in combination with imatinib for patients with gastrointestinal stromal tumors (GIST) that have progressed on imatinib. - It has a dose-escalation part to find the maximum tolerated dose and the recommended dose, while assessing safety, pharmacokinetics, and early antitumor activity, followed by an expansion part with three arms. - Arm A evaluates the combination in patients who progressed on imatinib at doses below the determined MTD; Arm B tests pimitespib alone and also explores giving imatinib after pimitespib; Arm C uses sunitinib monotherapy as a reference. - Eligibility includes histologically confirmed GIST, radiographic progression on or after imatinib, at least one measurable lesion, and ECOG 0-1 with informed consent. - Exclusion criteria include severe vision impairment, prior therapy beyond imatinib for advanced GIST, prior extensive gastrectomy or small-bowel resection, serious illness, other active cancers, and pregnancy or lactation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. is being studied. Conditions: Colorectal Cancer Metastatic • Eligibility: Inclusion Criteria: * Written informed consent to study procedures. * Histologically proven diagnosis of colorectal cancer. * Metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.…. Goal: The aim oh this study is to determine the safety and recommended dose of trifluridine/tipiracil plus capecitabine and bevacizumab combination (part 1, dose escalation phase) and to assess its activity in previously untreated mCRC patients who are deemed not eligible for intensive chemotherapy (part 2, expansion phase). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Gruppo Oncologico del Nord-Ovest.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. is being studied. Conditions: CRC • Eligibility: Inclusion Criteria: * Males or females, aged ≥ 18 years. * Participants with pathologically confirmed advanced Colorectal Cancer. * Participants have at least 1 target lesion other than…. Goal: This is a multicenter, open-label Phase Ib/II clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of the HS-20110 combination therapies in Patients with Advanced Colorectal Cancer. "Rolling 6" design would be used to conduct dose escalation part of this study. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Hansoh BioMedical R&D Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers is being studied. Conditions: Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer +3 • Eligibility: Diagnosis and Main Criteria for Inclusion/Exclusion: Inclusion Criteria Main Study - patients with MSS mCRC These criteria are applicable for both Dose Escalation and Expansion part of the…. Goal: This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Rottapharm Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers is being studied. Conditions: Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly +8 • Eligibility: Inclusion Criteria: * Age ≥65 years * Histologically confirmed non-metastatic or locally advanced gastrointestinal cancers (esophageal, gastric, colorectal, pancreatic, biliary tract) * Planned to receive adjuvant chemotherapy (standard…. Goal: This study evaluates the effectiveness of the G8 and VES-13 frailty scales in predicting chemotherapy-related toxicity in older patients with gastrointestinal cancers receiving adjuvant chemotherapy. Older adults are more vulnerable to treatment-related side effects due to age-related declines in physiological reserve. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Ankara Etlik City Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests how liver cancer (hepatocellular carcinoma, HCC) patients respond to interventional therapy combined with systemic therapy and how outcomes vary between individuals. It will look at outcomes like disease control, progression-free survival, patient-reported outcomes, and adverse reactions, and it will study clinical features and biomarkers that relate to this heterogeneity. The goal is to build a machine learning model to predict the risk of adverse reactions to help tailor decisions for each patient. The study is not yet recruiting and will enroll adults with HCC who are receiving or planning interventional therapy with systemic treatment (including DEB-TACE with targeted therapy and/or immunotherapy) or other local interventional treatments; it excludes people with other active cancers, severe cognitive impairment, very limited life expectancy, or decompensated liver function (Child-Pugh C).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery is being studied. Conditions: Colon Cancer, Gastrointestinal Cancer • Eligibility: Inclusion Criteria: 1. Recently diagnosed with nonmetastatic GI cancer, including but not limited to small bowel, colon, rectal, pancreatic, gastric, or hepatic malignancies, and scheduled for an elective…. Goal: To measure the efficacy of postbiotic supplements in mitigating the gut dysbiosis induced by colon cancer surgery. Efficacy in mitigating dysbiosis will be measured by the change in fecal Shannon Diversity Index (SDI) within patients from the baseline sample to various postoperative timepoints. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; University of South Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether inherited genetic changes influence the risk of colorectal cancer that starts at a young age and compares these findings to cancers that begin later in life. Researchers want to learn about the clinical features, tumor markers, family history, and how genetic results relate to survival and cancer recurrence. It is for MD Anderson Cancer Center patients with colon or rectal adenocarcinoma diagnosed between ages 18-50 (young-onset) or 51-80 (later-onset), and their first-degree relatives; participants must be able to speak English and provide informed consent. Participants complete questionnaires and provide blood or saliva samples, and data are collected over time through follow-up surveys and medical record review; the study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer is being studied. Conditions: Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectosigmoid Adenocarcinoma +10 • Eligibility: Inclusion Criteria: * HEALTHY SUBJECT: No known diagnosis of colorectal cancer (CRC) or any other type of cancer for the last 10 years.(basal cell skin cancer is allowed).…. Goal: This study looks at the level of circulating tumor elements (cancer cells or DNA pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). Researchers will also compare the level and genetic characteristics of circulating tumor elements between individuals with rectal cancer and healthy individuals to understand how they may change over time. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether adding the antidepressant fluoxetine to immunotherapy improves outcomes for people with advanced liver and gallbladder cancers. It is for adults 18 to 80 who have liver cancer or bile duct cancer that has spread or is locally advanced and who are about to start PD-1/PD-L1 inhibitor therapy, and who have depression or anxiety. The researchers want to learn if fluoxetine can better control the cancer, extend survival, and also improve mood and quality of life. Exclusions include active hepatitis B or C infection, a history of serious mental illness, fluoxetine allergy, or inability to take oral medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer is being studied. Conditions: Colon Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with KRASG12C mutation. KRASG12C on ctDNA may also be used as basis of eligibility, with…. Goal: To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer is being studied. Conditions: MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer • Eligibility: Inclusion Criteria: * Written and signed informed consent. * Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or * The estimated life expectancy of ≥3 months. *…. Goal: This is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety, tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced gastric adenocarcinoma and colorectal cancer during the perioperative period.Eligible patients will receive AK104 for three cycles before surgery and at most 6 months after surgery. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Peking University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) is being studied. Conditions: Breast Cancer, Breast Neoplasms, Colon Cancer +5 • Eligibility: Inclusion Criteria: * Patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care * WHO performance status…. Goal: This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations is being studied. Conditions: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast • Eligibility: Inclusion Criteria: * Adults ≥18 years old. Other age restrictions may apply as per local regulations. * Unresectable and/or metastatic solid tumors with pre-specified HER2 mutations (S310F, S310Y,…. Goal: This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests Trilaciclib to protect the bone marrow from chemotherapy in people with advanced biliary tract cancer (cholangiocarcinoma) or pancreatic cancer. It is for adults 18 and older who need chemotherapy and have a confirmed diagnosis, with enough health and follow-up ability. The study aims to learn about Trilaciclib’s safety and whether it reduces chemotherapy-related bone marrow suppression. Major exclusions include history of certain myeloid blood disorders, active brain metastases, pregnancy or lactation, recent major surgery or radiotherapy, and known allergy to the study drug.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving a Bile Duct Drainage Procedure in Patients With Inoperable Cancer Blocking the Bile Ducts: Comparing Two Types of Endoscopically Placed Internal Stents to Prevent Blockage of a Lumen Apposing Metal Stent is being studied. Conditions: Malignant Biliary Obstruction, Advanced Pancreatic Cancer and Cholangiocarcinoma, Inoperable Malignant Biliary Obstruction +1 • Eligibility: Inclusion Criteria: * Age ≥18 years. * Radiologically or histologically proven malignant distal bile duct obstruction with unresectable or metastatic disease, including those who have already failed ERCP…. Goal: This study looks at the best way to treat bile duct blockage in people with advanced cancer that cannot be removed by surgery. A blocked bile duct can cause serious symptoms like yellowing of the skin (jaundice), infection, and pain. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Waikato Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer is being studied. Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7 +3 • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically confirmed non-small cell lung cancer (cohort 1) or colorectal cancer (cohort 2) * Patients must have measurable disease, defined…. Goal: This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase 1/2 trial testing TC-510, a novel autologous engineered T cell therapy, in adults with advanced cancers that express mesothelin. TC-510 uses T cells modified with a mesothelin-targeting single-domain antibody fused to CD3 and a PD-1:CD28 switch receptor to boost activity against PD-L1–positive cancer cells. Eligible cancers include malignant pleural mesothelioma, serous ovarian adenocarcinoma, pancreatic adenocarcinoma, triple-negative breast cancer, and colorectal cancer, as long as the tumor shows mesothelin expression by immunohistochemistry. Participants must be 18 or older, have 1–5 prior systemic therapies for metastatic or unresectable disease, a good performance status (ECOG 0–1), be fit for leukapheresis, and have adequate organ function; key exclusions are inability to follow study procedures and known non-compliance or drug/alcohol use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparison Between Results of 2 Laparoscopic Surgical Procedures in Operable Colon Cancer Cases in Upper Egypt is being studied. Conditions: Colon Cancer Stage I, Colon Cancer Stage II • Eligibility: Inclusion Criteria: 1. Both sexes will be included. 2. Age: all adult patients. 3. All diagnosed patients with operable cancer colon. 4. Cancer at cecum, appendix, ascending colon,…. Goal: The investigators will assess and compare Surgical, pathological and oncological outcomes between two laparoscopic procedures conventional colectomy versus complete mesocolic excision for operable colon cancer cases in Upper Egypt Phase/Status/Sponsor: Unknown phase; COMPLETED; Sohag University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests peposertib together with avelumab and hypofractionated radiation therapy in adults with advanced or metastatic solid tumors and hepatobiliary cancers. - It aims to find a safe dose and assess how well this combination works, with Phase II focusing on hepatobiliary tumors and comparing against avelumab plus radiation alone by measuring objective response rate. - The study will also look at how the drugs are processed in the body and collect biomarker data to understand who may respond. - Eligibility notes include that Phase I excludes prior immune checkpoint therapy, while Phase II has some allowed prior checkpoint exposure under specific conditions; pregnancy is not allowed and certain autoimmune or CNS conditions exclude participation. - The study status is currently suspended.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tested the [18F]FAPI-74 PET scan to detect FAP-expressing cells in people with gastrointestinal cancers, including liver cancer, cholangiocarcinoma, gastric, pancreatic, and colorectal cancer. - It enrolled adults with confirmed GI cancers and used the PET scan after initial staging, comparing PET results with FAP immunohistochemistry as the primary objective and with histopathology as the secondary objective. - Participants needed a tissue sample from biopsy or planned biopsy/resection, no cancer treatment between tissue sampling and the PET scan, and informed consent. - Exclusions included pregnancy or breastfeeding, infections or serious illnesses that could affect FAP expression, recent use of another investigational agent, and known hypersensitivity to components of the tracer. - The study is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy is being studied. Conditions: Melanoma, Gastrointestinal Neoplasms, Genitourinary Cancer +2 • Eligibility: Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Diagnosed with non-small cell lung cancer (NSCLC) OR melanoma AND initiating therapy with single…. Goal: This research aims to identify clinical strategies to manage adverse events during immune checkpoint inhibitor therapy by (1) determining the impact of checkpoint inhibitors on metabolism through major CYP enzymes and (2) identifying associations between pro-inflammatory cytokine concentrations and negative clinical outcomes during checkpoint inhibitor therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Indiana University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tested whether adding hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil to biliary drainage improves survival for people with locally advanced, unresectable perihilar cholangiocarcinoma (pCCA). - It compared biliary drainage plus this chemotherapy approach against biliary drainage plus best supportive care. - Participants were adults aged 18–80 with locally advanced unresectable pCCA, good performance status, and adequate liver function; key exclusions included allergy to contrast or 5-FU, pregnancy, prior chemotherapy or radiotherapy, metastases, and serious comorbidities. - The study has completed and aimed to determine whether the combined treatment provides a survival benefit and acceptable safety.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy is being studied. Conditions: Colorectal Cancer, Precancerous Condition • Eligibility: DISEASE CHARACTERISTICS: * Scheduled to undergo colonoscopy at the Vanderbilt University Medical Center or the Tennessee Valley Veterans Administration Medical Center * No prior genetic colorectal cancer syndromes…. Goal: RATIONALE: Collecting and storing samples of tissue, blood, and other body fluids to test in the laboratory and gathering information about health and lifestyle from participants may help doctors learn more about cancer risk factors. PURPOSE: This clinical trial is looking at biological, genetic, and lifestyle risk factors for developing colorectal adenomas or polyps in participants undergoing colonoscopy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Vanderbilt University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study is being studied. Conditions: Breast Cancer, Colorectal Cancer, Prostate Cancer • Eligibility: Inclusion Criteria: 1. Age 65-90 2. Able to understand study procedures and to comply with them for the entire length of the study. 3. Diagnosis of Stage II-III…. Goal: The goal of this clinical trial is to test a new way to help older adults who have had cancer. The researchers want to see if a program that assesses participants health and aging is achievable and makes a difference. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, Davis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy is being studied. Conditions: Metastatic Colorectal Cancer, Pancreas Adenocarcinoma, Cholangiocarcinoma • Eligibility: Inclusion Criteria: Newly referred patients with advanced pancreatic cancer (\~20/year), Cholangiocarcinoma (\~20/year), metastatic colorectal cancer (mCRC) (\~50/year) and anti-EGFR-treated mCRC patients (\~10/year) to Oslo University Hospital are eligible…. Goal: Circulating tumor DNA assays are becoming relevant for routine diagnostics, but many related aspects are yet unresolved. With this project, the investigators aim to develop pragmatic molecular diagnostic pathways of liquid biopsies relevant in advanced gastrointestinal malignancies with focus on clinical utility and sensible use of resources. Phase/Status/Sponsor: Unknown phase; TERMINATED; Oslo University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors is being studied. Conditions: Gastric Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Has a pathologically or cytologically documented advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma and colorectal cancer that is refractory to or intolerable with standard…. Goal: This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jiangsu HengRui Medicine Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Peripheral Blood Protein Biomarkers for Colorectal Cancer Screening is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Patient aged 50 years or older referred for screening colonoscopy after a positive FIT test or for endoscopic resection of a previously identified suspicious colorectal…. Goal: The aim of the study is to validate the value of value of peripheral blood protein biomarkers in colorectal cancer screening, and to identify new ones Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Rouen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface is being studied. Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms • Eligibility: Inclusion Criteria: * Signed and dated, written informed consent form (ICF) (ICF1 for B7-H6 testing for all patients except those with advanced or metastatic colorectal cancer (CRC); and…. Goal: This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Brightline-2 trial tests whether brigimadlin (BI 907828) helps adults with advanced cancer of the biliary tract, pancreas, lung, or bladder. It’s for people whose cancer has not responded to standard treatment or for whom no standard treatment exists. Brigimadlin is taken as a tablet every 3 weeks, with regular visits to monitor tumor size and safety. Eligibility requires specific tumor biology (MDM2 amplification or TP53 wild-type) confirmed by tissue testing and measurable disease with good performance status. Key exclusions include prior brigimadlin or other MDM2/MDMX-p53 drugs, risk of significant bleeding, or conditions that could make participation unsafe. The study is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers is being studied. Conditions: Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung +2 • Eligibility: Inclusion Criteria: * Patients must have histological confirmation of solid metastatic cancer with at least one metastatic or primary lesion in the liver or lung/chest, except for group…. Goal: This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and nivolumab with or without stereotactic body radiation therapy and to see how well they work in treating patients with lung/chest or liver cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as BMS-986156, ipilimumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Using Visual Arrays to Support Understanding of Genetic Risk is being studied. Conditions: Decision Aid • Eligibility: Inclusion Criteria: * ability to read and understand English * opt-in consent Exclusion Criteria: * incorrect responses to validation questions. Goal: The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stephanie B. Seminara, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests ZW25 (zanidatamab) added to standard first-line chemotherapy in people with HER2-expressing gastrointestinal cancers that are unresectable or metastatic, specifically gastroesophageal adenocarcinoma, biliary tract cancer, or colorectal cancer. The study has two parts: Part 1 checks safety and tolerability and helps establish a recommended dose for the combination, and Part 2 evaluates the anti-tumor activity. Eligible participants have HER2-expressing tumors, are unresectable or metastatic, and have good performance status with adequate organ and heart function; colorectal cancer participants must have wild-type RAS/BRAF, with additional biomarker criteria by part. Key exclusions include prior HER2-targeted therapy, recent systemic cancer treatment (with limited exceptions), untreated brain metastases, significant cardiac disease, QTc prolongation, active infections, or uncontrolled HIV/HBV/HCV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Increase Colorectal Screening is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Individuals age 50 to 75 years, * One or more SYHC visits in the last year, * Not uptodate with CRC screening Exclusion Criteria: *…. Goal: The purpose of this study is to determine whether inreach and outreach strategies will be superior to usual care, and combination of both will be superior to either strategy alone. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, San Diego.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Yoga-Based Breathing Exercise, Colorectal Cancer Surgery is being studied. Conditions: Symptoms and Signs • Eligibility: Inclusion Criteria: * Having colo-rectal surgery for the first time * Have a mobile phone suitable for downloading the yoga-based breathing exercise video, * Use the same type…. Goal: This study was designed as a prospective, parallel two groups and randomized controlled study with an experimental-control group to evaluate the effect of yoga-based breathing exercise on pain, fatigue, insomnia and self-efficacy in individuals undergoing colorectal cancer surgery. The sample size of the study was conducted with 60 patients, 30 in the control group and 30 in the experimental group, according to the results of a similar study with the G\*Power 3.1., 9.7 program, with α = 0.05, 80% power and 0.648 effect, and taking into account possible losses. Phase/Status/Sponsor: Unknown phase; COMPLETED; KTO Karatay University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tested whether tumor tissue and blood can identify biomarkers that predict how advanced biliary tract cancer responds to a chemotherapy combination of gemcitabine, cisplatin, and nab-paclitaxel. It enrolled adults with biliary tract cancer that is unresectable, metastatic, or recurrent, who planned to receive the triplet chemotherapy after tumor sequencing. Researchers used biopsy samples for in-house sequencing and collected blood over time to study cell-free DNA and circulating tumor cells and their relation to response and progression. Eligibility required measurable disease and good performance status, with key exclusions including uncontrolled illness, prior palliative chemotherapy for BTC, and dementia or other conditions affecting consent. Status: COMPLETED; Sponsor: CHA University; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Treatment Strategy for Adult Congenital Biliary Dilation is being studied. Conditions: Congenital Biliary Dilation • Eligibility: Inclusion Criteria ： 1. Age: Adults (≥18 years). 2. Study population: Consecutive patients treated at Beijing Tsinghua Changgung Hospital. 3. Time frame: Underwent surgical treatment between November 2014…. Goal: The management of congenital biliary dilations (CBDs), including choledochal cysts, represents one of the most challenging areas in hepatobiliary surgery due to their potential implications for long-term morbidity and malignant transformation. While CBDs have a relatively low incidence in Western populations (1/150,000-1/100,000), the prevalence is notably higher in Asian countries (1/1,000), making it a significant global health concern. Phase/Status/Sponsor: Unknown phase; COMPLETED; Beijing Tsinghua Chang Gung Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer is being studied. Conditions: Undernutrition, Gastrointestinal Cancer • Eligibility: Case group selection criteria: Inclusion Criteria: * 18 years ≤ Age ≤ 80 years * Colorectal pancreatic cancer * Undernutrition related to cancer (weight loss \> 5% weight…. Goal: Undernutrition associated with cancer, or cancer cachexia results from a deterioration of the energy balance that leads to a gradual mobilization of energy reserves in the body and to increasing deterioration of the nutritional status of patients. This will thus significantly reduce quality of life and survival of patients with a lower tolerance to cancer treatments. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Tours.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparison of the ENDOCUFF VISION® Endoscopy Cap Coupled With GI GENIUS™ Artificial Intelligence Compared to Each Device Alone in Improving Colonic Adenoma Detection Rate During Colonoscopy is being studied. Conditions: Colorectal Cancer, Adenoma, Intestinal Polyps • Eligibility: Inclusion Criteria: * Need to perform colorectal cancer screening colonoscopy: * Primary Screening: Fecal Immunological Test positive; * Secondary screening: personal or family history of polyps, personal or…. Goal: Colorectal cancer is the 2nd most common cause of death by cancer. Screening is therefore essential, with a positive impact for prevention, and in the visualization and removal of colonic adenomas, pre-cancerous lesions of colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Centre Hospitalier Universitaire de Nīmes.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The Liver and Biliary Tumor Tissue Registry collects tissue from adults having surgery to remove a liver or biliary mass or from those having a biopsy, to store for future research. - A blood sample may also be collected at enrollment. - The goal is to support translational research on the biology, causes, and prognosis of liver and biliary diseases, including studies that may use patient-derived xenografts. - Eligibility: people scheduled for surgical resection of a liver or biliary mass; Exclusions: under 18 years old or prior radiation to the mass. - Status: terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.